On Sunday, March 12 at 2:00 a.m., Daylight Saving Time, we advance our clocks forward an hour to better utilize sunlight. While many lament “the loss” of an hour’s sleep, setting our clocks forward one hour can indeed disturb our sleep patterns and leave us groggy for several days.

In an effort to reduce the number of people who die needlessly from sudden cardiac arrest each year, NewYork-Presbyterian and the Ronald O. Perelman Heart Institute have launched the #HandsOnlyCPR campaign, an ambitious community awareness, education and activation effort with a simple, but powerful message: Everyone Can Save a Life.

Dr. Ralf Holzer, a pediatric cardiologist and expert in minimally invasive techniques to treat children and adults with congenital heart disease, has been named chief of the Division of Pediatric Cardiology at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and director of Pediatric Cardiac Catheterization at The Komansky Children’s Hospital, effective June 1.

NewYork-Presbyterian Brooklyn Methodist Hospital recently held its 2017 Nurse Recognition Awards Ceremony. More than 130 staff members were honored at the ceremony, including 13 who received special recognition.

An immunotherapy drug used in combination with a traditional cancer drug could be an effective approach to treating a rare cancer known as sarcoma, according to a new study. Co-authored by Dr. Gary Schwartz, chief of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center, the study found that a combination of nivolumab, a common cancer drug, and ipilimumab, an immunotherapy drug, is safe and effective for sarcoma patients who have tried all other options.

A technique to treat an irregular heartbeat that limits or eliminates patients’ exposure to radiation should be more widely adopted by physicians, NewYork-Presbyterian and Weill Cornell Medicine cardiologists argue in a new review article in Heart Rhythm, published in the June print issue and previously published online. They posit that the primary obstacle to the procedure’s widespread use – physicians’ discomfort with a different visual tool – can be overcome with training and experience.

NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy. The Phase 1 study has completed its second round of patient enrollment, with the first six patients having undergone dosing. The researchers will be discussing the trial on June 5 at the 2017 American Society of Clinical Oncology meeting in Chicago.

Women with preeclampsia, a common complication of pregnancy, face a heightened risk of stroke during pregnancy and postpartum if they have urinary tract infections, chronic high blood pressure, or clotting or bleeding disorders, according to a study by Columbia University Medical Center (CUMC) and NewYork-Presbyterian researchers.